DARATUMUMAB-BASED COMBINATION THERAPIES IN HEAVILY-PRE-TREATED PATIENTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA

被引：0
|
作者：
Lakshman, A. [1 ]
Abeykoon, J. [2 ]
Kumar, S. [1 ]
Rajkumar, V. [1 ]
Kourelis, T. [1 ]
Buadi, F. [1 ]
Dingli, D. [1 ]
Martha, L. [1 ]
Gonsalves, W. [1 ]
Dispenzieri, A. [1 ]
Kyle, R. [1 ]
Lin, Y. [1 ]
Go, R. [1 ]
Warsame, R. [1 ]
Hobbs, M. [1 ]
Fonder, A. [1 ]
Hwa, Y. [1 ]
Hayman, S. [1 ]
Russell, S. [1 ]
Leung, N. [1 ]
Gertz, M. [1 ]
Kapoor, P. [1 ]
机构：
[1] Mayo Clin, Div Hematol, Rochester, MN USA
[2] Mayo Clin, Internal Med, Rochester, MN USA
来源：
HAEMATOLOGICA | 2017年 / 102卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
E1240
引用
收藏
页码：508 / 508
页数：1
相关论文
共 50 条
  • [21] Health-related quality of life of carfilzomib- and daratumumab-based therapies in patients with relapsed/refractory multiple myeloma, based on German benefit assessment data
    Weisel, Katja
    Ludwig, Heinz
    Rieth, Achim
    Lebioda, Andrea
    Goldschmidt, Hartmut
    QUALITY OF LIFE RESEARCH, 2020, 29 (01) : 69 - 79
  • [22] Daratumumab triplet therapies in patients with relapsed or refractory multiple myeloma: A "real world" experience
    Fucci, Ludovica
    Gensini, Lorenzo
    Coppetelli, Ugo
    La Barbera, Elettra Ortu
    Gentile, Martina
    Fiori, Luciano
    Perrone, Salvatore
    Cimino, Giuseppe
    LEUKEMIA RESEARCH REPORTS, 2022, 17
  • [23] DARATUMUMAB-BASED COMBINATION REGIMENS IN ELDERLY (≥75 YEARS) PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: SUBGROUP ANALYSIS OF THE PHASE 3 CASTOR AND POLLUX STUDIES
    Mateos, M. -V.
    Spencer, A.
    Nooka, A.
    Pour, L.
    Weisel, K.
    Cavo, M.
    Laubach, J.
    Cook, G.
    Iida, S.
    Benboubker, L.
    Usmani, S. Z.
    Yoon, S. -S.
    Bahlis, N.
    Chiu, C.
    Schecter, J.
    Wu, K.
    Qin, X.
    Soong, D.
    Dimopoulos, M. A.
    HAEMATOLOGICA, 2017, 102 : 109 - 109
  • [24] EFFICACY OF DARATUMUMAB-BASED REGIMENS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA - A SYSTEMATIC LITERATURE REVIEW AND NETWORK META-ANALYSIS
    Dimopoulos, M. A.
    Weisel, K.
    Kaufman, J.
    Sonneveld, P.
    Rizzo, M.
    Xu, Y.
    Fahrbach, K.
    Gaudig, M.
    Slavcev, M.
    Dearden, L.
    Lam, A.
    HAEMATOLOGICA, 2017, 102 : 525 - 526
  • [25] Immunomodulation in Pomalidomide, Dexamethasone, and Daratumumab-Treated Patients with Relapsed/Refractory Multiple Myeloma
    Pierceall, William E.
    Amatangelo, Michael D.
    Bahlis, Nizar J.
    Siegel, David S.
    Rahman, Adeeb
    Van Oekelen, Oliver
    Neri, Paola
    Young, Mary
    Chung, Weiyuan
    Serbina, Natalya
    Parekh, Samir
    Agarwal, Amit
    Thakurta, Anjan
    CLINICAL CANCER RESEARCH, 2020, 26 (22) : 5895 - 5902
  • [26] Efficacy of daratumumab monotherapy in real-world heavily pretreated patients with relapsed or refractory multiple myeloma
    Salomon-Perzynski, Aleksander
    Walter-Croneck, Adam
    Usnarska-Zubkiewicz, Lidia
    Dytfeld, Dominik
    Zielinska, Patrycja
    Wojciechowska, Malgorzata
    Holojda, Jadwiga
    Robak, Pawel
    Pasternak, Anna
    Knopinska-Posluszny, Wanda
    Hawrylecka, Dorota
    Wojtowicz, Marcin
    Szeremet, Agnieszka
    Osowiecki, Michal
    Mordak-Domagala, Monika
    Zaucha, Jan Maciej
    Giannopoulos, Krzysztof
    Warzocha, Krzysztof
    Jamroziak, Krzysztof
    ADVANCES IN MEDICAL SCIENCES, 2019, 64 (02): : 349 - 355
  • [27] ECONOMIC EVALUATION OF DARATUMUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
    Salazar, A.
    Guirant Corpi, L.
    Aguirre, A.
    Herrera, M.
    Chacon, C.
    VALUE IN HEALTH, 2018, 21 : S254 - S254
  • [28] Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myeloma
    Gasparetto, Cristina
    Lentzsch, Suzanne
    Schiller, Gary
    Callander, Natalie
    Tuchman, Sascha
    Chen, Christine
    White, Darrell
    Kotb, Rami
    Sutherland, Heather
    Sebag, Michael
    Baljevic, Muhamed
    Bensinger, William
    Leblanc, Richard
    Venner, Chris
    Bahlis, Nizar
    Rossi, Adriana
    Biran, Noa
    Sheehan, Heidi
    Saint-Martin, Jean-Richard
    Van Domelen, Dane
    Kai, Kazuharu
    Shah, Jatin
    Shacham, Sharon
    Kauffman, Michael
    Lipe, Brea
    EJHAEM, 2021, 2 (01): : 56 - 65
  • [29] Is There a Role for Daratumumab Retreatment in Patients with Relapsed/Refractory Multiple Myeloma?
    Galusic, Davor
    Krecak, Ivan
    Blaslov, Viktor
    Opara, Andela Krstulovic
    Valkovic, Toni
    Kinda, Sandra Basic
    BIOMEDICINES, 2025, 13 (01)
  • [30] Immune Profiling of Relapsed or Refractory Multiple Myeloma Patients Treated with Pomalidomide and Low-Dose Dexamethasone in Combination with Daratumumab
    Pierceall, William E.
    Bahlis, Nizar
    Siegel, David S.
    Schiller, Gary J.
    Samaras, Christy J.
    Sebag, Michael
    Berdeja, Jesus G.
    Ganguly, Siddhartha
    Matous, Jeffrey V.
    Song, Kevin
    Seet, Christopher S.
    Talamo, Giampaolo
    Srinivas, Shanti
    Acosta-Rivera, Mirelis
    Bar, Michael
    Quick, Donald P.
    Anz, Bertrand
    Fonseca, Gustavo
    Reece, Donna
    Chung, Weiyuan
    Serbina, Natalya
    Zafar, Faiza
    Agarwal, Amit
    Thakurta, Anjan
    BLOOD, 2018, 132
12345